The group has established a dedicated new spin-out entity TiltBio Inc to drive the later-stage development of its lead asset (TILT-123).
TILT-123 (igrelimogene Iitadenorepvec) is a Phase II -ready asset targeting high unmet need cancers of HNSCC and other solid tumors. The asset has highly differentiated mechanism as a next-generation adenoviral immunotherapy with dual selectivity for tumor replication, utilizing a chimeric adenovirus design armed with TNF and IL-2. Intravenous delivery allows for potential commercial viability and easy combination.
A set of Phase I clinical trials of TILT-123 in various indications both as a monotherapy and in combination with immune checkpoint inhibitors or tumor-infiltrating lymphocyte (TIL) therapy have been completed with about 100 patients treated across the studies. Patient enrollment for the Phase I trials has now been completed. The obtained clean safety profile, allows pursuite of front-line development strategy in Phase II setting for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC). Additional applications for in different indications and combinations are under consideration.
Our Technology
The power of TILT® technology enables TILT’s proprietary oncolytic viruses to be encoded with immunostimulatory cytokines and molecules, which have potential applicability across a wide range of solid tumor cancers.
Learn more about how the technology works: